Article Information
History
- May 31, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Haraldur Þorsteinsson1,
- Hannes A. Baukmann2,
- Hildur S. Sveinsdóttir1,
- Dagmar Þ. Halldórsdóttir1,
- Bartosz Grzymala1,
- Courtney Hillman3,
- Jude Rolfe-Tarrant3,
- Matthew O. Parker3,
- Justin L. Cope2,
- Charles N. J. Ravarani2,
- Marco F. Schmidt2 and
- Karl Æ. Karlsson1,4,5,*
- 13Z, Menntavegur 1, 102 Reykjavík, Iceland
- 2biotx.ai GmbH, Am Mühlenberg 11, 14476 Potsdam, Germany
- 3Surrey Sleep Research Centre, School of Biosciences, University of Surrey, United Kingdom
- 4Reykjavik University, Biomedical Engineering, Menntavegur 1, 102, Reykjavik, Iceland
- 5Biomedical Center, University of Iceland, Vatnsmýrarvegur 16, 102, Reykjavik, Iceland
- ↵*e-mail: karlsson{at}ru.is
Posted May 31, 2024.
Validation of L-Type Calcium Channel Blocker Amlodipine as a Novel ADHD Treatment through Cross-Species Analysis, Drug-Target Mendelian Randomization, and clinical evidence from medical records
